Climb Bio, INC 10-K annual reports

Climb Bio, Inc. reported a net loss of $59.9 million for fiscal year 2025, while actively progressing its lead product candidates, budoprutug and CLYM116, through multiple clinical trials for immune-mediated diseases.

Climb Bio, a clinical-stage biotechnology company, reports its full year 2024 results and highlights progress in its pipeline of therapies targeting immune-mediated diseases, including budoprutug and CLYM116.

Eliem Therapeutics has filed an amendment to its annual report on Form 10-K, primarily to include information required by Part III regarding directors, executive compensation, and corporate governance.

Eliem Therapeutics outlines a transition, separation, and consulting agreement for an executive, including enhanced severance benefits and a consulting engagement.